证券代码：300725 证券简称：药石科技 南京药石科技股份有限公司投资者关系活动记录表 编号：2020-001 | --- | --- | --- | |-------------------------|-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活 \n动类别 | □现场参观 ■其他 | □特定对象调研 □分析师会议 □媒体采访 \n□业绩说明会 □新闻发布会 □路演活动 \n （电话会议） | | | | 本次电话会议由华泰证券股份有限公司组织召开，通过电话会议系统 | | 参与单位名称 及人员姓名 | 参与会议的投资者共 | 完成，参会人员名单由华泰证券提供，主要有国盛证券、上投摩根、 华泰柏瑞、中信证券、国金证券、农银汇理、浙商证券、亚太财险等， 319 名。 | | 时间 | 2020 年 ...

证券代码：300725 证券简称：药石科技 南京药石科技股份有限公司投资者关系活动记录表 编号：2019-002 | --- | --- | --- | --- | |-----------------------|---------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------| | 投资者关系活 \n动类别 | ■特定对象调研 □分析师会议 \n■现场参观 □其他 | ■媒体采访 \n□业绩说明会 □新闻发布会 □路演活动 \n（请文字说明其他活动内容） | | | | 深交所投教中心 刘俊余 | | | | | 证券时报 | 臧晓松 | | | 参与单位名称 | | 全景网 刘民江、张原、陈昊 | | | 及人员姓名 | 华泰证券 刘佳奇 | 等中小投资者 | | | | 南京证券 潘兰兰 ...

证券代码：300725 证券简称：药石科技 南京药石科技股份有限公司投资者关系活动记录表 编号：2019-001 | --- | --- | --- | --- | |--------------|--------------------------|---------|--------------------------------------------------| | 投资者关系活 | ■ | | 特定对象调研 □分析师会议 □媒体采访 | | | | | □业绩说明会 □新闻发布会 □路演活动 | | 动类别 | □ | | 现场参观 □其他 （请文字说明其他活动内容） | | | | | 国金证券 王班 交银施罗德 张胤 | | 参与单位名称 | | | 东吴证券 全铭 太平保险 姚宏福 | | | | | 东吴证券 焦德智 英大保险 王喆 | | 及人员姓名 | | | 银华基金 魏卓 中英人寿 朱睿 | | | 长城基金 龙宇飞 | | | | 时间 | 2019 年 7 月 | 16 日 | | | 地点 | 江苏省南京市高新区中丹园 | | B 座 15 楼 | | 上市公司接待 | 董事 ...

证券代码：300725 证券简称：药石科技 南京药石科技股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |--------------|-------|-------|-----------------------------------------------| | | | | | | | | | 编号： 2018-001 | | | ■ | | 特定对象调研 □分析师会议 □媒体采访 | | 投资者关系活 | □ | | 业绩说明会 □新闻发布会 □路演活动 | | 动类别 | □ | | 现场参观 □其他 （请文字说明其他活动内容） | | 参与单位名称 | | | 中信建投 袁清慧 兴业证券 孙媛媛 | | 及人员姓名 | | | 华泰证券 李沄、郭梁良 平安医药 倪亦道、邱晓旭 | | | | | 东兴证券 胡偌碧 中金公司 谭宸航、陈曦、帅为 | | | | | 华创证券 李民蔚、孙渊 国联证券 周静、邓国凤 | | | | | 国海证券 周超泽 南京证券 时松 | | | | | 广发证券 姚凯飞 华金证券 李伟 | | | | | 招商证券 李勇剑 东方财 ...

南京药石科技股份有限公司投资者关系活动记录表 编号：2022-01 证券代码：300725 证券简称：药石科技 | --- | --- | --- | --- | |--------------|------------------------------|--------------------------------------|--------------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | □媒体采访 | | 投资者关系活 | □ 业绩说明会 | | □新闻发布会 □路演活动 | | 动类别 | □现场参观 | □ | 其他（电话会议） | | 参与单位名称 | | | 国盛证券、上投摩根基金、民生加银基金、富安达基金等机构共 26 名 | | 及人员姓名 | 参与人员 | | | | 时间 2022 | 年 2 月 24 日 | | | | 地点 | 公司会议室 | | | | 上市公司接待 | 总经理 | 苗文芳 | 博士 | | 人员 | 财务总监 吴奕斐 | | | | | ...

Financial Performance - In the first half of the year, the revenue from CDMO services reached over 10 million, primarily from domestic clients [2] - The company maintains a cautious approach to capacity expansion, planning based on product pipeline and client demand [2] - The revenue from domestic clients in the CDMO sector is growing faster than that from overseas clients, with domestic revenue growth attributed to enhanced brand influence and successful project experiences [4] Client Engagement and Market Strategy - The company has a high project retention rate, indicating client satisfaction with services and technical capabilities [4] - The proportion of foreign clients in CDMO revenue is between 60% to 70%, while domestic clients account for 30% to 40% [3] - The company aims to deepen foreign clients' understanding of its CMC capabilities through market expansion efforts [4] Organizational Adjustments - The company restructured its R&D and CDMO divisions to better align with current business development needs, enhancing internal collaboration [4] - The financial reporting structure was adjusted to reflect the evolution of the business model, moving from weight-based classifications to molecular blocks and CDMO categories [4] New Drug Development - The New Drug Discovery Division has established high-quality compound libraries and has completed multiple target screenings, showing promising activity and drug-like properties [5] - Recent collaboration with Aidi Pharmaceutical on a 3CL protease inhibitor indicates ongoing advancements in drug discovery efforts [5]

Group 1: Financial Performance - The company achieved a 31% revenue growth in the first three quarters, with approximately 40% growth excluding large orders [4] - The molecular building block division experienced a growth rate of 44%, while the CDMO division grew by 28% [4] - The overall gross margin remains stable, with CDMO gross margin between 40%-45% and molecular building block gross margin between 55%-60% [4] Group 2: Market Expansion - The company has added 6,000 new molecular building block compounds to its inventory to meet overseas market demand [4] - In the domestic market, the company has gained recognition for its integrated CMC capabilities, engaging with 100 innovative drug companies and industry experts [2] - The management team has participated in multiple industry conferences in Europe and the US to enhance brand influence and attract new clients [2] Group 3: Operational Insights - The utilization rate of the existing workshop remains stable, with the new 502 workshop expected to reach normal production status by the end of the year [4] - The company is planning to launch the 503 workshop in the first half of 2023, with future workshops being designed as fully automated [4] - The increase in accounts receivable turnover days is attributed to the longer development cycle of API projects and some domestic clients experiencing slower payment due to funding issues [5] Group 4: Strategic Outlook - The company does not foresee significant impacts from international geopolitical factors on its business, as the demand for CDMO services remains strong [6] - The global CDMO market is highly fragmented, and the domestic CDMO sector is expected to grow at a rate higher than the global average [6] - The company has made optimizations in order acquisition and production delivery to reduce uncertainties in operations [6] Group 5: Emerging Business Areas - The company has formed a dedicated team to advance emerging business areas such as ADC, oligonucleotides, and PROTAC, with significant progress reported [6] - The company has completed research on all E3 ligases available in the market and is advancing linker design work [6]

Financial Performance - Revenue for Q3 2022 reached ¥450,058,731.03, an increase of 59.83% compared to the same period last year[5] - Net profit attributable to shareholders was ¥96,523,773.69, up 57.87% year-on-year[5] - Net profit excluding non-recurring items was ¥91,757,829.72, reflecting a 64.72% increase compared to the previous year[5] - Operating income increased by 107.42% to ¥19,198,057.75 compared to ¥9,255,542.90 in the same period last year[11] - Total operating revenue for the current period reached ¥1,184,702,109.49, a significant increase from ¥902,929,920.72 in the previous period, representing a growth of approximately 31.2%[32] - Net profit for the current period was ¥261,286,132.90, compared to ¥451,168,056.54 in the previous period, reflecting a decrease of approximately 42.2%[34] - Earnings per share for the current period were reported at 1.2570, compared to 2.2399 in the previous period, indicating a decline of approximately 43.8%[34] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥4,955,539,732.77, a 41.31% increase from the end of the previous year[5] - Current liabilities totaled approximately 1.28 billion yuan, compared to 788.88 million yuan in the previous year[28] - Long-term liabilities amounted to approximately 1.12 billion yuan, significantly higher than 90.33 million yuan in the previous year[28] - The company reported a total equity of approximately 2.55 billion yuan as of September 30, 2022[28] - The company’s total liabilities and equity increased to ¥4,955,539,732.77 from ¥3,506,922,491.19, reflecting a growth of about 41.3%[31] Cash Flow - Cash flow from operating activities for the year-to-date was ¥186,433,654.21, down 33.53% compared to the previous year[5] - Cash paid for purchasing goods and services increased by 38.58% to ¥596,044,900.65, primarily due to higher material procurement expenses[11] - Cash paid to employees surged by 79.20% to ¥352,418,090.14, reflecting an increase in workforce and salary expenses[11] - Cash received from borrowings rose significantly by 339.83% to ¥792,895,362.26, indicating increased bank loan amounts[11] - Cash paid for debt repayment increased by 240.48% to ¥409,679,206.00, reflecting higher repayments of due bank loans[11] - The company reported a net increase in cash and cash equivalents of $7,819,198.21, contrasting with a decrease of $374,555,376.31 in the prior period[41] Investment and Financing - Cash invested increased by 40.86% to ¥3,314,532,000.00, mainly due to higher purchases of financial products[11] - The company received cash from convertible bond fundraising amounting to ¥1,145,283,018.87, marking a new financing strategy[11] - Cash inflow from financing activities reached $1,938,178,381.13, a substantial rise from $180,273,159.65 in the previous period[41] - Net cash flow from financing activities improved to $1,004,307,342.88 from $40,005,468.30, reflecting a positive shift in financing operations[41] Research and Development - Research and development expenses rose by 48.79% to ¥121,203,263.82, indicating increased investment in innovation[10] - Research and development expenses increased to ¥121,203,263.82 from ¥81,457,397.06, marking a rise of approximately 48.8%[32] Shareholder Information - The total number of common shareholders at the end of the reporting period was 23,470, with the largest shareholder holding 20.69%[13] Revenue Breakdown - Revenue from the sub-block business reached 269 million yuan, a year-on-year increase of 44.19%[21] - CDMO revenue amounted to 909 million yuan, reflecting a year-on-year growth of 28.09%[21] - Domestic revenue was 372 million yuan, up 43.06% compared to the same period last year[21] - International revenue reached 812 million yuan, showing a year-on-year increase of 26.41%[21] - Overall gross margin for the first three quarters was 47.30%, slightly down from the previous year[21]

Financial Performance - PharmaBlock reported a revenue of RMB 300 million for the first half of 2022, representing a year-on-year increase of 25%[21] - The company's revenue for the first half of 2022 was ¥734,643,378.46, representing an increase of 18.23% compared to ¥621,349,416.99 in the same period last year[33] - Future guidance estimates a revenue growth of 20% for the second half of 2022, targeting RMB 360 million[21] - The company achieved a revenue of 735 million yuan, representing an 18.23% year-on-year growth; excluding the impact of a major client's project delivery cycle, revenue growth was 29.00%[64] - The company's operating revenue for the reporting period was ¥734,643,378.46, representing an increase of 18.23% compared to the same period last year[98] - The gross profit margin was 47.74%, slightly down from 49.64% in the previous year[65] - The gross profit margin for the CDMO segment was 43.17%, with a year-on-year decrease of 2.13%[101] Profitability and Expenses - Net profit attributable to shareholders decreased by 59.84% to ¥153,095,324.58 from ¥381,238,213.47 year-on-year[33] - Basic and diluted earnings per share fell by 60.10% to ¥0.77 from ¥1.93 in the same period last year[33] - The net cash flow from operating activities dropped significantly by 78.70%, amounting to ¥40,546,816.33 compared to ¥190,401,654.04 in the previous year[33] - R&D expenses amounted to 71.82 million yuan, an increase of 41.36% year-on-year, with an R&D expense ratio of 9.78%[65] - The company's human resources expenditure increased to 235.29 million yuan, a rise of 82.16% year-on-year, reflecting significant growth in personnel scale and compensation[65] Market Expansion and Client Base - User data indicates a 30% increase in the number of active clients compared to the same period last year, reaching 1,200 clients[21] - The company has expanded its market presence in Europe, achieving a 40% growth in sales in that region[21] - The company is actively expanding its customer base, with 26% of API and formulation CMC projects coming from long-term partnerships, and 40% of clients entering through CMC projects[69] - The number of kilogram-level terminal customers increased to 166, a year-on-year growth of 58%, with sales exceeding 5 million for 35 customers, up 30% year-on-year[70] Research and Development - The company plans to invest 15% of its revenue into R&D for new drug development and technology advancements[21] - PharmaBlock is focusing on the development of small molecule drugs, with 5 new compounds entering clinical trials by the end of 2022[21] - The company has established a diverse library of drug molecular building blocks, enabling rapid identification of candidate compounds for drug discovery[46] - The company has developed a high-standard one-stop CDMO service platform, providing comprehensive services for intermediates, APIs, and drug formulations[46] - The company has developed a library of 160,000 unique small molecule drug building blocks, significantly accelerating drug development for clients[50] - The company has implemented advanced continuous flow chemistry and micro-packed bed technologies, achieving industrial-scale production and reducing development cycles[53] Risk Management - The company has identified key risks including regulatory changes and supply chain disruptions, with strategies in place to mitigate these risks[21] - The company faced risks related to declining demand in the drug research and development market, which could negatively impact revenue growth if the global pharmaceutical market slows down[138] - The company has a high proportion of revenue from overseas sales, with contracts typically denominated in foreign currencies, exposing it to exchange rate fluctuations[141] Environmental Compliance - The company emphasizes environmental protection and safety in production, having not experienced major accidents, but acknowledges increasing pressure as business scales up[138] - The company has established a quality management system to ensure product quality, which is critical for its development[138] - The company has no reported instances of exceeding pollution discharge limits for wastewater, with total discharge amounts well within regulatory standards[161] - All companies reported no significant environmental pollution incidents during the reporting period[186] Employee Engagement and Governance - The company has implemented a stock incentive plan to enhance employee motivation and align their interests with shareholders[152] - Employee engagement initiatives included sports events and cultural activities, fostering a sense of belonging and enhancing team cohesion[195] - The company adheres to legal regulations and has improved its corporate governance structure to protect shareholder rights, ensuring timely and accurate information disclosure[192]

Financial Performance - PharmaBlock reported a cash dividend of 1.00 RMB per 10 shares to all shareholders, based on a total of 199,658,096 shares[5]. - The company's operating revenue for 2021 was CNY 1,201,629,070.94, representing a 17.55% increase from CNY 1,022,229,215.88 in 2020[30]. - The net profit attributable to shareholders in 2021 was CNY 486,559,403.95, a significant increase of 164.14% compared to CNY 184,207,681.24 in 2020[30]. - The net profit after deducting non-recurring gains and losses was CNY 232,996,748.92, up 34.24% from CNY 173,573,289.18 in 2020[30]. - The basic earnings per share for 2021 was CNY 2.46, a 148.48% increase from CNY 0.99 in 2020[30]. - The total assets at the end of 2021 were CNY 3,506,922,491.19, with net assets attributable to shareholders increasing by 44.60% to CNY 2,427,424,730.19[30]. - The company reported a net cash flow from operating activities of CNY 238,029,950.44, a decrease of 12.33% from CNY 271,505,518.45 in 2020[30]. - The company achieved a total revenue of 1.202 billion RMB in 2021, representing a year-on-year growth of 17.55%[63]. - The net profit attributable to shareholders reached 487 million RMB, marking a significant year-on-year growth of 164.14%[64]. - The gross profit margin for 2021 was 48.13%, showing a stable improvement compared to 2020[64]. - The company reported a total revenue of 32,104,530, with a net profit of 11,034,117, representing a decrease of 43,035,247 compared to the previous period[175]. - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 25% year-over-year growth[191]. Research and Development - The company specializes in the research, development, production, and sales of drug molecular building blocks, with a focus on innovative chemical products and services in the global drug development field[5]. - The company invested 114 million RMB in R&D expenses, which is a 25.40% increase year-on-year, with an R&D expense ratio of 9.49%[64]. - The number of R&D personnel increased to 243 in 2021, up 25.26% from 194 in 2020[106]. - R&D expenditure reached ¥114,023,944.60 in 2021, representing 9.49% of operating revenue, compared to 8.89% in 2020[106]. - The company has established a library of 150,000 unique drug molecular building blocks, significantly aiding clients in drug development[53]. - The company has developed advanced manufacturing models for biopharmaceutical products, focusing on green, safe, and intelligent production[50]. - The company has achieved breakthroughs in continuous flow chemistry, fixed-bed technology, and biocatalysis, enhancing its service offerings[50]. - The company constructed a virtual compound library containing over 10 billion compounds, significantly enhancing its drug discovery capabilities[83]. - The company aims to increase R&D investment, expanding service categories to include new drug types such as oligonucleotides, PROTAC, and ADC[151]. - Research and development expenses increased by 10%, totaling $80 million, reflecting the commitment to new technology advancements[191]. Market and Business Strategy - Future strategies may include market expansion and the development of new products and technologies[5]. - The company is focused on enhancing its capabilities in drug discovery and development through innovative chemical engineering technologies[103]. - The company has established a project pipeline with 1,430 projects in the preclinical to Phase II stages and 45 projects in Phase III to commercialization[65]. - The company has expanded its customer base, increasing the number of kilogram-level terminal customers to 144, a year-on-year growth of 15.5%, and the number of customers with sales exceeding $5 million to 58, a growth of 28%[68]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and enhance operational capabilities[179]. - The company plans to expand its market presence and enhance product development, focusing on innovative technologies and new product launches[179]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of $100 million allocated for this purpose[191]. - The company plans to invest $20 million in digital marketing to boost brand awareness and customer engagement[191]. - The company is focused on improving its human resources planning and establishing a digital platform for talent management[153]. Risk Management - The company faces various risks including policy changes, intensified market competition, and potential declines in gross margin due to customer project progress[5]. - The report highlights potential impacts on sales growth due to the progress of clients' drug development projects[5]. - The company is committed to maintaining quality control and addressing environmental and safety production risks[5]. - The company has faced delays in project completion due to environmental control and weather factors[133]. Governance and Compliance - The company has established a comprehensive governance structure, ensuring effective decision-making and compliance with legal regulations[158]. - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[160]. - The company has established an independent financial department with specialized personnel, ensuring financial operations are separate from controlling shareholders[163]. - The company has a clear and independent asset ownership structure, with no legal disputes or potential disputes regarding its assets[163]. - The company has a well-defined corporate governance structure, including a shareholders' meeting, board of directors, and supervisory board, all operating independently[163]. Subsidiaries and Acquisitions - The company completed the acquisition of a 16.5% stake in Zhejiang Huishi, which became a subsidiary, resulting in a gain of CNY 222,274,540.92 from the revaluation of previously held shares[36]. - The company has initiated the establishment of new subsidiaries, including Shanghai Yaoshiyuan and Jiangxi Shangshi, which are yet to commence operations[149]. - The acquisition of Zhejiang Huishi is expected to strengthen the company's strategic development and resource integration[149]. - The subsidiary, American Yaoshi, reported total assets of CNY 260,737.144 million and a net profit of CNY 2,924.841 million[143]. - The company recorded a net loss of 7,602,827.93 for the subsidiary Yaojiankangke, indicating challenges in profitability[146]. Sustainability and Social Responsibility - The company is committed to achieving carbon neutrality goals while enhancing operational efficiency and reducing energy consumption[151]. - The management team emphasized a focus on sustainability initiatives, aiming to reduce carbon emissions by 30% over the next five years[191].